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Abstract. Leptospirosis is a potentially fatal emerging zoonosis with worldwide distribution and a broad range of
clinical presentations and exposure risks. It typically affects vulnerable populations in (sub)tropical countries but is
increasingly reported in travelers as well. Diagnostic methods are cumbersome and require further improvement.
Here, we describe leptospirosis among travelers presenting to the GeoSentinel Global Surveillance Network. We
performed a descriptive analysis of leptospirosis cases reported in GeoSentinel from January 1997 through De-
cember 2016. We included 180 travelers with leptospirosis (mostly male; 74%; mostly tourists; 81%). The most
frequent region of infection was Southeast Asia (52%); the most common source countries were Thailand (N = 52),
Costa Rica (N = 13), Indonesia, and Laos (N = 11 each). Fifty-nine percent were hospitalized; one fatality was
reported. We also distributed a supplemental survey to GeoSentinel sites to assess clinical and diagnostic prac-
tices. Of 56 GeoSentinel sites, three-quarters responded to the survey. Leptospirosis was reported to have been
most frequently considered in febrile travelers with hepatic and renal abnormalities and a history of freshwater
exposure. Serology was the most commonly used diagnostic method, although convalescent samples were re-
ported to have been collected infrequently. Within GeoSentinel, leptospirosis was diagnosed mostly among in-
ternational tourists and caused serious illness. Clinical suspicion and diagnostic workup among surveyed
GeoSentinel clinicians were mainly triggered by a classical presentation and exposure history, possibly resulting in
underdiagnosis. Suboptimal usage of available diagnostic methods may have resulted in additional missed, or
misdiagnosed, cases.
INTRODUCTION
Leptospirosis is an emerging zoonotic disease, causing
more than a million severe cases worldwide and around
60,000 deaths annually.1 The disease-causing spirochetes of
the Leptospira genus2 display complex transmission pat-
terns.3 A wide range of infecting serovars exist in a broad
range of host animals, most notoriously in rats.2 Well-known
major risk factors are water associated, such as recreational
water activities; water exposure following ﬂoods and heavy
rain; contact with animal or animal urine such as rodents and
livestock; and poor sanitation.3 Less common risk factors in-
clude exposure through open skin wounds and soil contact,3
which might occur while gardening4,5 or walking barefoot.3
Moreover, leptospirosis has emerged as an important prob-
lem in urban slums in the developing world, where rat-borne
transmission increasingly triggers outbreaks.6–11 Most cases
are sporadic; however, outbreaks do occur and may be in-
creasingly frequent because of climate change.12
Clinical manifestations can vary from a mild self-limiting
infection to life-threatening illness. However, patients seeking
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care typically present with amild acute febrile illness including
chills, headache (often with retro-orbital pain), conjunctival
suffusion, photophobia, myalgia, abdominal pain, nausea,
vomiting, and sometimes transient exanthema.2,13 About
10% of patients progress to severe disease, including Weil’s
disease, characterized by jaundice, acute kidney failure, or
(pulmonary) hemorrhage.2,13–16 Pulmonary hemorrhage can
also be a stand-alone manifestation. Aseptic meningitis may
be seen in up to 25% of leptospirosis cases.13 Cardiac in-
volvement is likely more common than recognized.13 The list
of differential diagnoses for the evaluating clinician to consider
is long, encompassing, among others, malaria, arboviral in-
fections, rickettsial diseases, and typhoid fever,13,17 and
misdiagnosis is common.6,18–20 Early recognition and treat-
ment may be essential to improve patient outcomes13,21,22
and minimize hospitalization costs.
Establishinganearly, rapid, andaccuratediagnosis remains
a complex matter. Widely used serological tests that detect
antibodies, including themicroscopic agglutination test (MAT,
the current reference test) and immunoglobulin M enzyme-
linked immunosorbent assay (IgM ELISA), are not suitable for
early diagnosis as antibodies only appear in the blood about
5–10 days after the onset of symptoms.2 Leptospirae can be
cultured from blood in the early stages of disease, but this
process can take weeks or months.2,17 Molecular detection
tests, such as polymerase chain reaction (PCR), are increas-
ingly used for routine diagnosis of the disease in the ﬁrst week
of illness23–25 but are not yet available in all countries.26,27
Commercially available multiplex panels, testing for multiple
pathogens, could be amore accessible alternative.28 For early
presentations, PCR is recommended, if possible in combi-
nation with culture. For later presentations, MAT and IgM
ELISA are suggested. Convalescent samples should be col-
lected, and a combination of the previously described tests is
always preferable.24
The disease burden of leptospirosis is highest in resource-
poor, tropical countries; the highest incidence rates occur in
Oceania, Southeast Asia, the Caribbean, and East Africa.1,29
Notably, international travel to these regions now consti-
tutes a major independent risk factor for acquisition of
leptospirosis.30,31 In 2015, almost 1.2 billion international
tourist arrivalswere recordedworldwide,with anever-growing
number of travelers visiting tropical and subtropical regions.32
With travelers being increasingly engaged in high-risk recre-
ational activities, such as white-water rafting,33 growing num-
bers of travelers with leptospirosis returning from tropical
countries have been reported.4,31,33–37 In aGeoSentinel analysis
(1996–2011) of acute and potentially life-threatening tropical
disease among 3,666 ill travelers from higher resource areas,
leptospirosis was the fourth most common diagnosis.38
Here, we describe the epidemiology of leptospirosis among
travelers reported to the GeoSentinel Surveillance Network
since its inception more than 20 years ago (January 1997 until
December 31, 2016). In addition, we report our analysis of the
reported diagnostic approaches used by current GeoSentinel
Surveillance Network members, through a supplemental
survey among GeoSentinel sites.
METHODS
Data source–GeoSentinel surveillance system. Geo-
Sentinel is a global surveillance network designed to monitor
travel-related morbidity. It was established in 1995, with sys-
tematic data collection beginning in 1997.39,40 Currently, 70
GeoSentinel travel and tropical medicine clinics, located in 31
countries on six continents, contribute anonymous clinician-
based surveillance information on ill travelers with a focus on
infections acquired during travel (see http://www.istm.org/
geosentinel for an up-to-date site distribution map and other
information). In brief, for inclusion in the GeoSentinel data-
base, patients must have crossed an international border
within 10 yearsof presentation andsoughtmedical care froma
GeoSentinel site for a presumed travel-associated condition.
Standard data collection forms capture patient demographic
characteristics, detailed recent travel itinerary, countries vis-
ited within 5 years, reason for recent travel, symptom-based
grouping by affected organ system, and whether there was a
reported encounterwith a health-care provider before travel.40
Final diagnoses are assigned by the attending clinician and
chosen from a list of standard diagnosis codes, guided by
GeoSentinel diagnostic deﬁnitions. Each patient may have
more than one travel-related diagnosis, and each diagnosis is
reported as conﬁrmed, probable, or suspected, based on the
strength of the diagnosis.40 All GeoSentinel sites use the best
reference diagnostic methods available in their own country.
Clinical treatments and outcomes are not routinely reported.
GeoSentinel’s data collection protocol is for public health
surveillance andhas received adetermination of non-research
by a Centers for Disease Control and Prevention human
subjects’ advisor.
GeoSentinel surveillance data inclusion criteria and
deﬁnitions. GeoSentinel records for patients with a post-
travel diagnosis of “conﬁrmed” leptospirosis and a clinic visit
date from January 1, 1997 to December 31, 2016 were in-
cluded. GeoSentinel-deﬁned criteria for “conﬁrmed” lepto-
spirosis diagnosis state, “a compatible clinical history (e.g.,
fever with associated symptoms) plus positive microscopy,
culture, histopathology, nucleic acid ampliﬁcation test, anti-
gen detection, or seroconversion with a ³ 4× titer rise on se-
rology.” Furthermore, only patients presenting within 30 days
after return from travel were included, based on the incubation
period of leptospirosis of 2–30 days (average 7–10 days).17
Patients seen during travel, missing travel itinerary data, or
havinganon-ascertainable regionof exposurewere excluded.
The reason for travel was stratiﬁed into four categories: tour-
ism, business, visiting friends and relatives, and others (com-
bining small numbers of foreign aid and missionary workers or
military deployment).
Data source—supplemental GeoSentinel network survey.
A 21-question multiple-choice survey (Supplemental Material 1)
aimed to assess clinical and diagnostic practices among the
GeoSentinel sites. After piloting among selected sites, the sur-
vey was distributed by e-mail between December 2015 and
March 2016 to 56 GeoSentinel sites active at the time of the
survey, excluding the site of survey origin (Amsterdam). Re-
minders to complete the survey were sent twice via separate
e-mails. Each site was permitted one response. In case of mul-
tiple responses, incomplete surveys or the last submitted survey
were discarded.
Data management and analysis. A descriptive analysis of
data from the GeoSentinel surveillance system, including
demographics, travel characteristics, and symptoms, was
performed. Simple frequency statistics were calculated for
categorical variables. Analysis of symptoms only included
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data from October 2015 onward, the point where revised
methods for collection of symptom data were implemented.
Data from before this date are known to be incomplete. Data
on the method of diagnosis have been only been captured in
GeoSentinel sinceOctober 2015; similar data are not available
for patients seen before that time. Data were analyzed using
Microsoft Excel (2010) and SAS Enterprise Guide v5.1 (SAS
Institute, Inc., Cary, NC). TheGeoSentinel network surveywas
distributed in Survey Monkey® (www.surveymonkey.com).
Results were directly exported to, and descriptively analyzed
in, Microsoft Excel (2010). The vector map was created using
an open source vector map (https://commons.wikimedia.org/
wiki/Atlas_of_the_world) and further edited using Adobe® Il-
lustrator® CS6 (Adobe Systems Incorporated, San Jose, CA).
Further statistical analyses of GeoSentinel data, which is
not population-based, are not appropriate or advised. Such
methods are limited by the biases that are introduced by each
site and by their distribution, and may be misleading. These
data are most appropriately analyzed descriptively, except in
speciﬁc circumstances, none of which apply here.
RESULTS
Between January 1, 1997 and December 31, 2016, 227
patients with “conﬁrmed” leptospirosis were entered into
GeoSentinel; 180 met the inclusion criteria. Reasons for ex-
clusion were as follows: seen during travel (22), clinic visit
date > 30 days after return (14), missing travel itineraries (5), or
other incomplete information (6). The ﬁrst patientwas reported
in 1999; few were entered during 1999–2007 (< 5 per year),
then increased to 7 per year in 2008–2009, rising to 14–29
cases yearly thereafter (Figure 1). During the same period, the
number of GeoSentinel sites increased.
Table 1 provides an overview of demographic and travel
characteristics. Most of the patients were male and the me-
dian agewas 32 years (range 14–72 years). Themost common
reason for travel was tourism (81%). Many of the reported
infections were acquired in Southeast Asia (N = 93, 52%).
Common source countries of infection were Thailand (N = 52),
Costa Rica (N = 13), Indonesia (N = 11), and Laos (N = 11)
(Figure 2). Fifty-nine percent of patients were hospitalized;
there was one death. Female patients with leptospirosis were
hospitalized less frequently than male patients, and travelers
to Southeast Asia were hospitalized slightly more frequently
than patients infected in other regions (Table 2). For 22 pa-
tients, more than one diagnosis was registered (Supplemental
Material 2).
Analysis of symptoms only included data from October
2015 onward. Figure 3 shows signs and symptoms among the
30 travelers with leptospirosis as the only diagnosis. Fever,
headache, fatigue, and myalgia were reported frequently.
Data on the method of diagnosis were only available for 44
records. Twenty-two (50%) patients were diagnosed by se-
rology (MAT, IgM ELISA, and/or a rapid test) alone, 12 (27%)
by a nucleic acid ampliﬁcation test (e.g., real-time PCR or
loop-mediated isothermal ampliﬁcation) alone, ﬁve by both
methods (11%), two by microscopy (5%), one by a nucleic
acid ampliﬁcation test and culture (2%), and two by other
methods (not speciﬁed).
Survey results. Of 56 sites solicited, 42 (75%) completed
the survey. Eighty-eight percent of the responding sites were
academic institutions; 81% of respondents diagnosed 1–10
travelers with leptospirosis per year in the past 5 years; 19%
had not yet diagnosed any. Most sites (88%) were able to
obtain leptospirosis diagnostic test results within 2 weeks.
Key survey questions and responses, information on avail-
ability and usage of diagnostic methods, and key suspicion-
raising exposures andclinical symptomsare shown in Table 3.
Supplemental Material 1 shows an overview of all questions
and responses.
Half of the respondents (52%) considered leptospirosis in
“nonspeciﬁc febrile illness”; only 7% performed diagnostics
for leptospirosis in the majority of those cases. A majority of
respondents (66%) reported not testing for leptospirosis
without a compelling exposure history, equating to testing
of < 10% of travelers with unspeciﬁed febrile illness returning
FIGURE 1. Travelers diagnosed with leptospirosis (N = 180) and the number of reporting sites in the GeoSentinel Network, January 1, 1999–
December 31, 2016. The number of patients with leptospirosis meeting inclusion criteria in the GeoSentinel Network during 1999–2016 (grey
columns) and the number of sites reporting to GeoSentinel (black line).
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from endemic areas. The decision to request diagnostic
testing was inﬂuenced by suitable exposure histories (76%),
exclusion of alternative established causes such as arboviral
infections (48%), and certain laboratory abnormalities (60%).
Clinical severity was reported to have no inﬂuence on testing
by 69%of respondents. Most sites (63%) continued to search
for a deﬁnitive diagnosis (in > 50%of patients), even when the
patient was improving after empiric antibiotic therapy. Sixty
percent of respondents would prescribe empiric doxycycline
after exclusion of key differential diagnoses such as malaria,
typhoid fever, andarboviral infections (SupplementalMaterial 1).
DISCUSSION
GeoSentinel surveillance data. Leptospirosis was an in-
frequent diagnosis among febrile returning travelers in Geo-
Sentinel, but was identiﬁed mostly among those who had
traveled for tourism purposes. With increasing popularity of
tourism in tropical areas,32 including active, environmental
exposures like rafting, canoeing, and triathlons, the risk of
leptospirosis acquisition among travelers may be increasing,
as illustrated in previous case reports.37,41,42 Known high-risk
areas, such as Southeast Asia and Central America, were the
most common regions of exposure in our database. The top
countries where leptospirosis was acquired, Thailand, Costa
Rica and Laos, are not necessarily known to be most
endemic,1,43 but rather have higher numbers of travelers who
arepotentially engaged in freshwater recreational activities. The
epidemiology of leptospirosis worldwide1,43 should be con-
sidered when evaluating the ill traveler presenting with fever.
Increased risk of leptospirosis has recently been observed
in more temperate regions,34,44,45 possibly inﬂuenced by cli-
mate change or different types of risk activities.12,45 Case
series have reported signiﬁcant proportions of travelers in-
fected within Europe as well.4,33,35,46 In the Netherlands, 318
imported cases of leptospirosis were diagnosed between
1925 and 2008; 134 (42.1%) were acquired in Asia and 132
(41.5%) in Europe. France is a major tourist destination, with
one of the highest reported leptospirosis incidences in
Europe.44 Because travelers returning ill from developed
temperate-zone countries may be less likely to visit Geo-
Sentinel clinics, patients with leptospirosis acquired in those
regions may be underrepresented here.
An overall increase in patients with leptospirosis reported
within the GeoSentinel network was observed over time;
however, this was likely associated with an increase in the
number of sites reporting in the network in the same period.
Alternatively, it is possible that clinicians have become more
aware of the illness and that the wider introduction of PCR
provided an option for more accurate diagnosis.
Only one fatality was reported to GeoSentinel, despite the
potential risk of mortality associated with leptospirosis1;
however, the GeoSentinel surveillance approach may not
capture deaths efﬁciently.38
Most patients in this series were in the 18- to 49-year age
group and reported nonspeciﬁc symptoms, consistent with
other published reports.33,46,47 Fever was present in almost all
patients; neurologic and respiratory symptoms were present
in lower proportions than found in other reports13 but similar to
a small case series in travelers.37 It is also possible that the
disease presentation was different in these travelers than is
typically seen in leptospirosis in endemic areas. Other possi-
bilities are that leptospirosis was not recognized in patients
presentingwith those rarer reported symptoms, that theywere
treated with empiric doxycycline, or that patients with these
more severe forms of disease presented elsewhere. A pro-
spective study would be needed to better address these
uncertainties.
Most patients were male, although the proportion of female
patients (26%)was higher than in someother large case series
(reported proportions of < 10%).33,37,46,47 A higher proportion
of the reported hospitalized cases were male compared with
female patients, akin to other reports.33,48 Some possible
factors that can contribute to male predominance in lepto-
spirosis include a greater tendency to participate in high-risk
outdoor activities, later presentation for medical evaluation,
androgenic steroids andother biologic factors,48,49 or a higher
infectious inoculum. The relatively high percentage of female
patients in our analysis could signal a shift in behavior of fe-
male travelers, increasing their risk of contracting the dis-
ease. Female travelers should be considered equally at risk as
those who are male with respect to leisure exposure, and
leptospirosis should be routinely considered when evaluating
the febrile returned female traveler.
TABLE 1
Demographic and travel characteristics of travelers diagnosed with
leptospirosis in theGeoSentinel Network, January 1, 1999–December
31, 2016, N = 180*
Characteristic Number %
Male 132 74%
Median age in years (range) 32 (14–72)
Age groups
£ 17 years 4 2%
18–34 years 94 53%
35–49 years 46 26%
50–64 years 30 17%
³ 65 years 3 2%
Pretravel advice obtained
Yes 64 37%
No 83 47%
Unknown 28 16%
Travel reason
Tourism 145 81%
Business 15 8%
Missionary/volunteer/researcher/aid
work
9 5%
Visiting friends and relatives 9 5%
Military 1 1%
Travel duration in days (range)† 21 (5−165)
Time from return to presentation in days
(range)
9 (1–28)
Hospitalization 96 63%
Death 1 0.7%
Region of exposure
Southeast Asia 93 52%
Central America 24 13%
South America 15 8%
Sub-Saharan Africa 14 8%
Caribbean 12 7%
South Central Asia 8 4%
Oceania 4 2%
North Africa 2 1%
Australia and New Zealand 1 1%
Middle east 1 1%
Northeast Asia 1 1%
North America 1 1%
Western Europe 1 1%
Not ascertainable 1 1%
*Not all cells add to 180 because of missing data.
†Among travelers who traveled to only one country (N = 121).
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Site survey. Leptospirosis is an infection that is frequently
underdiagnosed, especially in mild disease presentations.17
In our survey among GeoSentinel clinicians, all reported see-
ing relatively few leptospirosis patients each year (< 10).
The majority of respondents (75% of all sites) worked at an
academic institution, where leptospirosis diagnostics are
expected to be readily available. Molecular detection tech-
niques are the cornerstone of diagnosis of leptospirosis in
the acute phase,26 but were available in only half of the
clinics, and were actually used in less than a third of the
clinics. In addition, convalescent samples were reported to
have been collected in a minority of cases after a negative
acute serology, despite the fact that antibodies only appear
in the blood 5–7 days or sometimes after 10 days or longer
following disease onset.2 Possibly, patients with mild dis-
ease improved on treatment and abandoned follow-up,
forgoing further testing.
Half of the clinicians considered leptospirosis in a case of
“nonspeciﬁed febrile illness,” but very few actually performed
diagnostics for it. Few clinicians reported testing patients
without a suggestive exposure history. Classical exposures,
such as freshwater contact and ﬂoods, were well known
among clinicians. In the general population, the infection
mechanism often remains unclear, and often there is no
classical exposure history.3 Data on travelers are scarce,
but the case series that exist do report clear exposure
histories.35,37 Nevertheless, preselecting patients based
only on a well-deﬁned exposure history may result in under-
diagnosis of leptospirosis among patients without a clear-
cut exposure, especially when they returned from highly
endemic areas.
Although the classicWeil’s triad of fever, jaundice, and renal
failure, with or without accompanying hemorrhagic features,
was well recognized, other severe disease manifestations
were less known among GeoSentinel Surveillance Network
respondents. Aseptic meningitis can occur in up to 25% of
cases,13 but this manifestation was recognized by relatively
few respondents (31%). Pulmonary hemorrhage is an
TABLE 2
Distribution of gender and exposure regions with hospitalization
status among travelers diagnosed with leptospirosis in the
GeoSentinel Network, January 1, 1999–December 31, 2016*
Inpatient n (%) Outpatient n (%)
Female 21 (46) 25 (54)
Median age (range) 29 (18–56) 28 (14–72)
Male 86 (66) 44 (34)
Median age (range) 35.5 (16–66) 33 (19–59)
Median age, overall (range) 33 (16–66) 31 (14–72)
Southeast Asia 52 (63) 31 (37)
Central America 14 (58) 10 (42)
South America 9 (60) 6 (40)
Sub-Saharan Africa 6 (43) 8 (57)
Caribbean 6 (50) 6 (50)
South Central Asia 5 (63) 3 (37)
Oceania 2 (50) 2 (50)
North Africa 1 (50) 1 (50)
Australia and New Zealand 0 (0) 1 (100)
North America 1 (100) 0 (0)
Northeast Asia 1 (100) 0 (0)
Western Europe 1 (100) 0 (0)
*N = 180; 110 inpatients, 70 outpatients. Not all cells add to 180 because of missing data.
FIGURE 2. Exposure countries among travelers diagnosed with leptospirosis in the GeoSentinel Network, January 1, 1999–December 31, 2016
(N=167).*† *Includesonlypatients forwhomcountryof exposuredatawereavailable.†Purple represents52patientsexposed inThailand.Darkblue
represents countries with 10–20 exposed patients (13 for Costa Rica and 11 each for Laos and Indonesia). Medium blue represents countries with
5–9 exposed patients (nine for Colombia and ﬁve for Malaysia). Light blue represents countries with < 5 patients (four for Philippines; three each for
Cambodia, Gabon, Jamaica, Mexico, and Panama; two each for Brazil, Dominican Republic, Ecuador, Guadeloupe, India, Martinique, Papua New
Guinea, Peru, Sri Lanka, and Trinidad and Tobago; and one each for Afghanistan, Bangladesh, Botswana, Burkina Faso, Central African Republic,
China, Democratic Republic of the Congo, Egypt, El Salvador, France, Ghana, Guatemala, Mauritius, Morocco, Nepal, New Zealand, Nicaragua,
Palau, Puerto Rico, Reunion, Samoa, Sierra Leone, South Africa, Togo, Turkey, United States, and Vietnam. This ﬁgure appears in color at www.ajtmh.org.
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important but under-recognized form of the disease, and
outbreakswithonly thismanifestationhavebeendescribed.14,16
Almost half of the respondents did not include leptospirosis in
the differential diagnosis of the febrile traveler presenting with
hemorrhagic disease manifestations in the absence of the
classic Weil’s triad. In this analysis of returned travelers, the
lesser known disease manifestations were not frequently re-
ported, possibly because of the nature of symptom data col-
lection in GeoSentinel, which combines speciﬁc symptoms into
broad systemic categories.40
The results of our survey on clinical practices in specialized
travel medicine settings suggest that the number of lepto-
spirosis cases in travelers reported in the GeoSentinel Sur-
veillance system is likely to be an underestimate. This may be
due to suboptimal access to diagnostic testing at many sites,
especially in the setting where acute disease is encountered.
Furthermore, we found that the diagnosis of leptospirosismay
not be routinely consideredwhen clear-cut exposure histories
are absent and when some rather typical clinical features are
missing. Basedonour site survey, there is a need for improved
awareness among clinicians about the spectrum of expo-
sures, clinical presentations, and diagnostic considerations.
Strengths and limitations. In addition to those already
discussed, the GeoSentinel surveillance data have several
other limitations and may not be generalizable to the traveler
population as a whole.38,50–52 GeoSentinel reporting may be
biased toward capture of more complicated or more severe
disease because most GeoSentinel sites are also academic
institutions. Overall, hospitalization may be underestimated in
GeoSentinel, but there are some sites that almost exclusively
capture data from the inpatient setting. Therefore, the high
proportion of hospitalizations should be interpreted carefully.
Furthermore, leptospirosis may have been missed among
travelers presenting with atypical exposures or symptoms, or
presentations of milder, self-limited disease, and may have
had an inﬂuence on the results. GeoSentinel preferentially
captures travelers returning from tropical regions because of
the nature of the clinics thatmake up the network; so, travelers
with disease acquired in temperate regions are likely un-
derrepresented. GeoSentinel criteria for diagnosing patients
with leptospirosis may differ from the deﬁnitions used by na-
tional reference laboratories and other reporting systems,
limiting direct comparison with data from those sources. De-
spite these limitations, this is one of the largest series of lep-
tospirosis in travelers published to date and provides valuable
information about the epidemiology of leptospirosis in in-
ternational travelers.
A limitation of the network survey is that the answers were
captured from clinicians specialized in travel medicine and
maynot be representative of all clinical practices in aparticular
institution. Furthermore, the data are self-reported and may
therefore not be reﬂective of actual practice. Some questions
allowed multiple answers, leading to respondents choosing
incompatible answers, making the interpretation more com-
plex. However, the relatively high response rate of 75% of
GeoSentinel sites in our view accounts for a representative
survey among our global network of mostly academic travel
clinics.
FIGURE 3. Proportion of reported signs or symptoms among patients diagnosed with leptospirosis in the GeoSentinel Network, October 31,
2015–December 31, 2016 (N = 30, patients with one diagnosis only). Clinical symptoms reported in recognized disease in patients with one
diagnosis, fromOctober 31, 2015 onward,when a revised coding systemof symptoms inGeoSentinelwas started. Reportingmay be incomplete in
GeoSentinel andmay not reﬂect the complete disease course, but rather the initial symptoms. *Other symptomswere not speciﬁed. †Less frequent
reported symptoms (< 5%, or one person each) included constipation, diffuse rash, focal rash, itch, neck stiffness/photophobia, skin lesion/
superﬁcial infection, and weight loss.
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CONCLUSION
Leptospirosis may be an infrequently encountered cause of
substantial morbidity among international travelers that may
not be clinically suspected. Although leptospirosis was most
frequently diagnosed among persons visiting highly endemic
countries, it may occur elsewhere and warrants broader
consideration in the differential of the ill traveler. Given
the laboratory diagnostic challenges and nonspeciﬁc pre-
sentation of many clinically evident cases, the burden of
reported disease is likely underestimated, as supported by
other published data.1,18–20 We recommend enhancement
of awareness about leptospirosis and heightened clinical
suspicion when evaluating the ill traveler. Laboratories need
to have up-to-date diagnostic methods available; molecular
detection techniques are key to early diagnosis, which is
helpful for the early initiation of treatment that may sub-
stantially reduce morbidity and improve outcomes. Empiric
treatment in cases of high suspicion is recommended. Efforts
to improve knowledge among clinicians regarding (the often
unclear) exposures and clinical presentations are needed.
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TABLE 3
Selected results of a GeoSentinel supplemental site survey regarding
clinical and diagnostic practices for leptospirosis
What exposures raise your suspicion of leptospirosis?
(multiple answers possible) n % (of 42)
Freshwater contact 42 100
Natural disasters (e.g., ﬂoods) 36 86
Any travel to endemic areas 29 69
Animal contact 28 67
Soil contact 18 43
Use of freshwater for cleaning and other
activities
12 29
Gardening 11 26
Which clinical presentation makes you
suspect leptospirosis (multiple answers
possible)
Febrile illness with liver enzyme or renal
function abnormalities
31 74
Febrile illness and jaundice 29 69
Febrile illness and conjunctival suffusion 26 62
Febrile illness and myalgia 23 55
Febrile illness with hemorrhagic
manifestations
23 55
Nonspeciﬁc febrile illness 22 52
Febrile illness with headache 17 41
Febrile illness with clinical signs of
meningitis
13 31
Febrile illness with exanthema 12 29
Febrile illness and respiratory symptoms 12 29
All of the above 17 41
How often do you perform diagnostics for
leptospirosis in the ﬁrst diagnostics workup
in patients with unspeciﬁed febrile illness
from endemic areas?
% (of 41)
< 10% of cases 25 61
10–30% of cases 9 22
31–50% of cases 4 10
> 50% of cases 3 7
How often do you test for leptospirosis in
patients without a ﬁtting exposure history?
Never 11 27
In < 10% of cases 16 39
In 10–30% of cases 10 24
In 31–50% of cases 0 0
In > 50% of cases 4 10
What diagnostics for leptospirosis are
available in your clinical setting? (multiple
answers possible)
ELISA 30 73
PCR 19 46
MAT 14 34
Serological rapid test (RDT) 13 32
Culture 9 22
Do not know 4 10
Which diagnostic test for leptospirosis do you
usually request? (multiple answerspossible)
ELISA 24 59
PCR 12 29
MAT 12 29
Serological rapid test (RDT) 12 29
Determined by the laboratory 9 22
Determined by duration of clinical illness 6 15
Culture 3 7
Do not know 1 2
Approximately how often are convalescent
samples collected for leptospirosis
diagnostics after a negative ﬁrst test?
% of 40
< 20% 19 48
20–40% 9 23
41–60% 4 10
61–80% 3 8
> 80% 5 13
ELISA = enzyme-linked immunosorbent assay; MAT = microscopic agglutination test;
PCR = polymerase chain reaction; RDT = rapid diagnostic test.
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